Hearing loss caused by a group of antibiotics called aminoglycosides could be prevented if patients were screened for a genetic mutation before treatment, say experts in this week's BMJ.
Aminoglycosides are most useful for the treatment of serious infections, such as septicaemia, complicated urinary tract infections, and tuberculosis.
Presbycusis
Presbycusis (age related hearing loss) is the gradual loss of hearing that occurs as people get older. Presbycusis involves progressive sensorineural hearing loss.
Advertisement
Their potential for ototoxicity (damage to the ear) is well known, but less well known is that some people have an inherited predisposition that renders them highly sensitive to these effects and can result in severe and permanent hearing loss, write Maria Bitner-Glindzicz and Shamima Rahman at the Institute of Child health in London.
The mutation, known as m.1555A-G is thought to cause up to 5% (1 in 40,000) cases of deafness in children in the UK. This is low compared to other countries. Studies from New Zealand and the US, for example, found between 1 in 206 and 1 in 1,161 positive cases in newborns.
![Deaf Awareness Week 2007]( "Deaf Awareness Week 2007")
This week, September 24th- 30th is celebrated worldwide as the Deaf Awareness Week.
Even in the absence of exposure to aminoglycosides, some families carrying this mutation may also develop deafness, albeit at a later age and with a lower penetrance.
In Spain, for example, 27% of families with at least two deaf individuals were positive for this mutation and everyone with the mutation who was exposed to aminoglycosides became deaf. By the age of 30, the probability of becoming deaf if an individual had received such antibiotics was 96.5% compared with 39.9% if they had never been treated.
Thus aminoglycosides are a major environmental modifier of the m.1555A-G mutation, say the authors.
But is it cost effective to screen for this mutation before aminoglycosides are given? The current cost of testing for this mutation in the UK is about £35 per test. However, this is based on a small number being performed and demand for more tests would reduce the costs. In contrast, the cost to the health service for a child who becomes deaf is estimated to be £61,000 over a lifetime, and an additional £18,000 a year in educational costs.
In the US, the total lifetime cost to society for a child who becomes deaf before acquiring language has been estimated to exceed $1m.
Hearing loss induced by aminoglycosides in individuals with the m.1555A-G mutation is preventable, they say. The mutation is well known among doctors who see patients who already have hearing loss. However, the general medical community is not aware of this susceptibility and that mutation testing is available.
They recommend in this BMJ editorial that the true prevalence of the mutation in the UK be ascertained to determine the cost effectiveness of screening everyone prescribed aminoglycoside antibiotics. In the meantime, patients who are likely to receive multiple courses of aminoglycosides - for example, patients with leukaemia and newborns admitted to special care baby units - should be screened.
Genetic testing needs to be turned around rapidly and consideration should be given to using an alternative antibiotic until the result of genetic testing is known, they conclude.
Source: BMJ
SRM
Deaf Awareness Week 2007
This week, September 24th- 30th is celebrated worldwide as the Deaf Awareness Week.
Advertisement
Even in the absence of exposure to aminoglycosides, some families carrying this mutation may also develop deafness, albeit at a later age and with a lower penetrance.
In Spain, for example, 27% of families with at least two deaf individuals were positive for this mutation and everyone with the mutation who was exposed to aminoglycosides became deaf. By the age of 30, the probability of becoming deaf if an individual had received such antibiotics was 96.5% compared with 39.9% if they had never been treated.
Thus aminoglycosides are a major environmental modifier of the m.1555A-G mutation, say the authors.
But is it cost effective to screen for this mutation before aminoglycosides are given? The current cost of testing for this mutation in the UK is about £35 per test. However, this is based on a small number being performed and demand for more tests would reduce the costs. In contrast, the cost to the health service for a child who becomes deaf is estimated to be £61,000 over a lifetime, and an additional £18,000 a year in educational costs.
In the US, the total lifetime cost to society for a child who becomes deaf before acquiring language has been estimated to exceed $1m.
Hearing loss induced by aminoglycosides in individuals with the m.1555A-G mutation is preventable, they say. The mutation is well known among doctors who see patients who already have hearing loss. However, the general medical community is not aware of this susceptibility and that mutation testing is available.
They recommend in this BMJ editorial that the true prevalence of the mutation in the UK be ascertained to determine the cost effectiveness of screening everyone prescribed aminoglycoside antibiotics. In the meantime, patients who are likely to receive multiple courses of aminoglycosides - for example, patients with leukaemia and newborns admitted to special care baby units - should be screened.
Genetic testing needs to be turned around rapidly and consideration should be given to using an alternative antibiotic until the result of genetic testing is known, they conclude.
Source: BMJ
SRM
Prescribing Antibiotics for ENT Infections is Unnecessary
A new study has found that an unwarranted use of antibiotics is on the high that are prescribed to curb possible complications after upper respiratory tract infection, sore throat, or ear infection.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Light therapy enhances sleep and psycho-behavioral symptoms in Alzheimer's patients with minimal side effects.
Electrical stimulation improves Alzheimer's patients' cognitive function and correlates with restored cortical plasticity.
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.